Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinicopathologic Features of Advanced Squamous NSCLC

Published byなお あわたけ Modified over 5 years ago

Similar presentations

Presentation on theme: "Clinicopathologic Features of Advanced Squamous NSCLC"— Presentation transcript:

1 Clinicopathologic Features of Advanced Squamous NSCLC
Mark A. Socinski, MD, Coleman Obasaju, MD, PhD, David Gandara, MD, Fred R. Hirsch, MD, Philip Bonomi, MD, Paul Bunn, MD, Edward S. Kim, MD, Corey J. Langer, MD, Ronald B. Natale, MD, Silvia Novello, MD, PhD, Luis Paz-Ares, MD, Maurice Pérol, MD, Martin Reck, MD, Suresh S. Ramalingam, MD, Craig H. Reynolds, MD, David R. Spigel, MD, Thomas E. Stinchcombe, MD, Heather Wakelee, MD, Carlos Mayo, MD, Nick Thatcher, MD, PhD  Journal of Thoracic Oncology  Volume 11, Issue 9, Pages (September 2016) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Relative risk for lung cancer based on smoking status in men. CI, confidence interval. Adapted with permission from Pesch et al.35 Copyright © 2012 John Wiley & Sons, Inc. All Rights Reserved. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Distribution of lung cancer by histologic type in (A) women and (B) men, 1998–2002. US, United States; UK, United Kingdom; sqCLC, squamous cell lung cancer. Adapted with permission from Youlden et al.38 Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Estimated frequency of genetic alterations in squamous cell lung cancer based on analysis of 178 samples from The Cancer Genome Atlas study. Alterations were defined as somatic mutations, homozygous deletions, high-level focal amplifications, or significant upregulation or downregulation of gene expression. FGFR1, FGFR1 fibroblast growth factor receptor 1 gene; FGFR2, FGFR2 fibroblast growth factor receptor 2 gene; FGFR3, FGFR3 fibroblast growth factor receptor 3 gene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; PTEN, phosphatase and tensin homolog; GRAF, GRAF Rho GTPase activating protein 26 gene; AKT3, AKT/serine threonine kinase 3 gene. Adapted with permission from the Cancer Genome Atlas Research Network.69 Copyright © 2012 International Association for the Study of Lung Cancer. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Clinicopathologic Features of Advanced Squamous NSCLC"

Similar presentations

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD 

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD 
Advances in Molecular Biology of Lung Disease

Advances in Molecular Biology of Lung Disease
Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD 

Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD 
Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network 

Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network 
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk  Ping Yang, MD,

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk  Ping Yang, MD,
Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance)  Arnaud Augert, PhD,

Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB (Alliance)  Arnaud Augert, PhD,
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.
Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E

Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E
Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network 

Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network 
Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD 

Adi F. Gazdar, MD, Fred R. Hirsch, MD, PhD, John D. Minna, MD 
Scientific Advances in Lung Cancer 2015

Scientific Advances in Lung Cancer 2015
Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification  Anna Karlsson, MSc,

Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification  Anna Karlsson, MSc,
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC  Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC  Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,

Similar presentations

Ads by Google